Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
Gyre Therapeutics (GYRE) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Gyre Therapeutics's actual EPS was $0.02, beating the estimate of $0.03 per share, resulting in a 53.00% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
